ARV stands for antiretroviral, a class of medications that treat HIV by stopping the virus from making copies of itself inside the body. When taken consistently, ARVs reduce the amount of virus in the blood to undetectable levels, which keeps the immune system healthy and eliminates the risk of sexually transmitting HIV to others. As of 2024, roughly 31.6 million people worldwide (about 77% of those living with HIV) take these medications.
How ARVs Stop HIV From Spreading in the Body
HIV works by hijacking a specific type of immune cell, then using that cell’s machinery to produce more copies of itself. Left unchecked, the virus gradually destroys these immune cells and weakens the body’s ability to fight infections. ARVs interrupt this process at different stages.
To replicate, HIV needs to convert its genetic material into a form the host cell can read, then stitch that material into the cell’s own DNA, and finally assemble new virus particles from long protein chains. Each of those steps depends on a specific viral enzyme. ARVs are designed to jam those enzymes so they can’t do their jobs. Without functioning enzymes, the virus can’t complete its life cycle, and replication grinds to a halt.
The Main Types of ARV Drugs
There are seven recognized categories of antiretrovirals, but most treatment regimens rely on combinations drawn from four major classes:
- Reverse transcriptase inhibitors (NRTIs and NNRTIs): These block the enzyme HIV uses to convert its RNA into DNA. Without this conversion, the virus can’t insert its genetic instructions into the host cell. Two sub-types exist: one mimics the building blocks of DNA to disrupt the process, and the other binds directly to the enzyme to disable it.
- Protease inhibitors (PIs): After an infected cell produces long, inactive protein chains from HIV’s blueprint, a viral enzyme called protease cuts those chains into smaller, functional pieces. Protease inhibitors wedge into the enzyme’s structure and prevent it from making those cuts, leaving the virus with unusable proteins.
- Integrase inhibitors (INSTIs): These are the newest major class. They block the enzyme that HIV uses to insert its genetic material into the host cell’s DNA. Without integration, the virus can’t commandeer the cell to produce new copies.
- Entry inhibitors: Rather than targeting enzymes inside the cell, these drugs prevent HIV from entering the cell in the first place, either by blocking the virus from fusing with the cell membrane or by blocking the receptor it uses to latch on.
Modern HIV treatment almost always combines drugs from multiple classes into a single daily pill. This multi-target approach makes it much harder for the virus to develop resistance, since it would need to mutate around several different drugs simultaneously.
How Quickly ARVs Work
Current guidelines recommend starting ARVs immediately at diagnosis, or as soon as possible afterward. The median time from starting treatment to reaching viral suppression is about 41 days. “Viral suppression” means the amount of virus in the blood drops so low that standard tests can’t detect it, typically below 200 copies per milliliter.
Reaching undetectable status isn’t just a lab milestone. The CDC states that a person living with HIV who maintains an undetectable viral load has zero risk of transmitting the virus to sexual partners. This principle, known as U=U (Undetectable equals Untransmittable), has fundamentally changed how HIV is understood and managed.
Why Consistency Matters
HIV mutates rapidly. Every time the virus replicates, there’s a chance it produces a slightly altered version of itself. If drug levels in the body drop because of missed doses, the virus gets an opportunity to multiply. Some of those new copies may carry mutations that make them resistant to one or more ARV drugs. Once drug-resistant strains take hold, the current regimen stops working and treatment needs to be switched to a different combination.
Even occasionally skipping doses increases this risk. That’s why adherence (taking medications exactly as prescribed, at the same time each day) is considered the single most important factor in long-term treatment success.
Injectable ARVs: An Alternative to Daily Pills
For people who find daily pills difficult to manage, an injectable option now exists. This two-drug combination is given as a pair of injections (one for each active ingredient) by a healthcare provider every one or two months. Before starting the injections, there’s a 28-day oral trial period involving two pills per day to make sure the medications are well tolerated.
Clinical trial participants have reported that the injectable option is more convenient and easier to integrate into daily life. It removes the need to remember a daily pill, pack medications for travel, or worry about others seeing pill bottles. On the other hand, the every-two-month schedule has shown slightly higher rates of drug resistance compared to the monthly schedule, so the dosing interval is a decision made on an individual basis. Patients on the injectable regimen typically pick a consistent day each month for their appointment, with a seven-day window on either side for flexibility.
Side Effects: Short-Term and Long-Term
Early ARVs were notorious for serious side effects, including fat redistribution (lipodystrophy) and nerve damage. Modern regimens are significantly better tolerated, but side effects haven’t disappeared entirely. Short-term reactions when starting treatment can include nausea, fatigue, and headaches, which often resolve within the first few weeks.
The bigger concern with lifelong treatment is cumulative effects over years or decades. Long-term risks that doctors monitor for include cardiovascular disease, changes in cholesterol and blood sugar, reduced bone mineral density, kidney dysfunction, and neuropsychiatric effects like mood changes or sleep disturbances. These aren’t inevitable. When a specific drug causes a problem, doctors can often swap it for another drug in the same class or a different class without interrupting viral suppression. Cholesterol changes, for example, can sometimes be managed with lifestyle adjustments or additional medication.
Rarely, an ARV can trigger a severe allergic reaction or significant liver inflammation. These are medical emergencies that require stopping all ARV medications immediately and restarting with a completely different combination. These serious reactions are uncommon with current first-line regimens but are screened for carefully during the early weeks of treatment.
ARVs for Prevention, Not Just Treatment
The same drugs used to treat HIV are also used to prevent it. Pre-exposure prophylaxis (PrEP) involves HIV-negative people taking ARVs to dramatically reduce their risk of acquiring the virus. Post-exposure prophylaxis (PEP) is a short course of ARVs taken after a potential exposure, such as a needlestick injury or unprotected sex with someone whose HIV status is unknown. In both cases, the drugs work by blocking the same viral enzymes, preventing HIV from establishing itself in the body before it can take hold.